TIDMUPR
RNS Number : 5032G
Uniphar PLC
27 July 2021
Uniphar plc
Half Year Trading Update and Notice of Results
Dublin, London | 27 July 2021: Uniphar plc (the "Group" or
"Uniphar"), an international diversified healthcare services
business servicing the requirements of more than 200 multinational
pharmaceutical and medical technology manufacturers, today
announces the following unaudited trading update for the six months
ended 30 June 2021.
The strong momentum, highlighted in the recent AGM statement on
May 12th, has continued throughout the period. The Group achieved
organic gross profit growth of 11%. The strong organic growth was
driven by continued outperformance in the Commercial & Clinical
division complemented by strong performances in the Product Access
and Supply Chain & Retail divisions. During the period, the
Group continued to invest in additional operational overhead, at
both divisional and Group level, to support future growth of the
Group.
Earlier this month Uniphar completed the acquisition of CoRRect
Medical GmbH, a Germany-headquartered company that specialise in
the commercialisation and distribution of medical device products
in the interventional cardiology sector across Germany and
Switzerland. This creates a strong presence for Uniphar in Germany,
the largest Medtech market in Europe.
Outlook
Uniphar remains confident in delivering on current year
expectations and the Group's medium term organic growth targets at
a divisional level remain unchanged.
M&A will continue to play an important part in Uniphar's
growth strategy and will continue to manage an active pipeline of
acquisition opportunities.
Commercial & Clinical
The Group remains focused on its strategy of building a
pan-European presence and continues to leverage existing
relationships into new geographies during the period. The
acquisition of CoRRect Medical GmbH, completed earlier this month,
represents a key milestone for this division, given the strategic
importance of the German market for current and prospective
clients. This acquisition is highly synergistic and will quickly be
complemented by organic opportunities from existing Uniphar
clients. The Group is targeting mid-single digit organic growth in
gross profit in this division in the medium term.
Product Access
Uniphar's Product Access platform creates a unique capability to
design and implement compliant, patient centric Expanded Access
Programs ("EAPs") globally. The integration of acquisitions
completed throughout 2020, including two US acquisitions, is
proceeding in line with strategic plans. The Group is targeting
double digit organic growth in gross profit in this division in FY
2021.
Supply Chain & Retail
Uniphar's market leading position in Ireland, in a two-player
Supply Chain market, is re-enforced by a growing symbol group
offering of retail pharmacies (359). The Integration of Hickey's
Pharmacy Group, acquired in 2020, is on track. Despite ongoing
COVID-19 related restrictions this division has performed
resiliently during the period. The Group is targeting low single
digit organic growth in gross profit in this division in FY
2021.
Ger Rabbette, Uniphar Group Chief Executive Officer said:
"Our trading update reflects a strong start to the year with the
Group delivering double-digit organic gross profit growth. I am
pleased to report that all our divisions are performing well, with
the outperformance in Commercial & Clinical representing a
particularly strong result.
The integration of our domestic and US acquisitions completed
last year continues and in line with our strategic plans.
Furthermore, the acquisition of CoRRect Medical GmbH, announced
earlier this month, provides the Group with an acceleration in its
organic entry into the highly attractive German Market, as we
continue to build out our pan-European platform in Commercial &
Clinical.
We remain confident and are on track to achieve our strategic
objective of doubling EBITDA within 5 years of IPO."
Notice of Results
The Group expects to publish its interim results for the six
months ended 30th June 2021 at 07:00 am (EST) on 1st September
2021.
A conference call for analysts and investors will be held at
9.00 am (BST) on the day to discuss the Group's results. Analysts
and investors who wish to participate should visit www.uniphar.ie
to register.
The Company's interim results press release and presentation
will be available on the website at 07.00 am (BST) on 1(st)
September 2021 at www.uniphar.ie .
--- Ends ---
For further details contact:
Uniphar +353 (0) 1 428 7777
Brian O'Shaughnessy
------------------------------
Group Director of Corporate Development investor.relations@Uniphar.ie
------------------------------
Davy +353 (0) 1 679 6363
------------------------------
(Joint Corporate Broker, Nominated Adviser
and Euronext
Growth Adviser)
------------------------------
Barry Murphy
------------------------------
Niall Gilchrist
Lauren O'Sullivan
------------------------------
RBC Capital Markets (Joint Corporate Broker) +44 (0) 20 7653 4000
------------------------------
Jonathan Hardy
------------------------------
Thomas Debrosse
------------------------------
Jamil Miah
------------------------------
Stifel Nicolaus Europe Limited (Joint Corporate
Broker) +44 (0) 20 7710 7600
------------------------------
Matt Blawat
------------------------------
Ben Maddison
------------------------------
Francis North
------------------------------
Q4 PR
+353 (0) 1 475 1444
or
------------------------------
(Public Relations Adviser to Uniphar) +353 87 235 6461
------------------------------
Iarla Mongey
------------------------------
About Uniphar plc
Headquartered in Dublin, Ireland, Uniphar plc is an
international diversified healthcare services business, servicing
the requirements of more than 200 multinational pharmaceutical and
medical technology manufacturers across three divisions -
Commercial & Clinical, Product Access and Supply Chain &
Retail.
The Group has strong established relationships with 7 of the top
10 pharma companies and 6 of the top 10 medical device companies.
With more than 3,000 colleagues, the Group is active in Ireland,
the UK, Germany, Switzerland, the Benelux, the Nordics, and the US,
delivering unlicensed and specialty medicine on a global basis.
The Group's vision is to improve patient access to
pharmaco-medical products and treatments by enhancing connectivity
between manufacturers and healthcare stakeholders. Uniphar
represents a strong combination of scale, growth and
profitability.
Commercial & Clinical
In Commercial & Clinical the Group provides sales, marketing
& distribution solutions to multinational pharmaceutical and
medical device manufacturers on an outsourced basis. Active in
Ireland, the UK, Germany, Switzerland, the Benelux, and the
Nordics, the Group is growing with its clients to provide
pan-European solutions. Uniphar has built a fully integrated
multi-channel solution that is supported by highly experienced,
clinically trained teams to deliver exceptional outcomes for all
clients.
Product Access
In Product Access the Group is growing two distinct service
offerings: 1) "On Demand Access", which are pharmacy led solutions
for sourcing and supplying unlicensed medicines to meet the needs
of both retail and hospital pharmacists; and 2) "Exclusive Access",
which are manufacturer led solutions for controlling the release of
speciality medicines for specifically approved patient populations
in agreed markets. The Group currently delivers product access
solutions on a global basis.
Supply Chain & Retail
Uniphar is an established market leader in Ireland with over a
50% market share in the wholesale/hospital market, supported by a
network of c.359 owned, franchised and symbol group pharmacies. The
business supports the diverse customer base through the provision
of strong service levels coupled with innovative commercial
initiatives. Supply Chain & Retail is an Irish only business
for the Group, although the manufacturer relationships and
infrastructure are utilised for the benefit of the growth
divisions, Commercial & Clinical and Product Access.
, the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTGZGZNKVFGMZM
(END) Dow Jones Newswires
July 27, 2021 02:00 ET (06:00 GMT)
Uniphar (LSE:UPR)
Historical Stock Chart
From May 2024 to Jun 2024
Uniphar (LSE:UPR)
Historical Stock Chart
From Jun 2023 to Jun 2024